Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE LA 160 50 versus VISKEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE LA 160 50 versus VISKEN.
INDERIDE LA 160/50 vs VISKEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propranolol: Non-selective beta-adrenergic receptor antagonist (blocks β1 and β2 receptors). Hydrochlorothiazide: Thiazide diuretic inhibiting Na+/Cl- cotransporter in distal convoluted tubule, reducing intravascular volume by increasing sodium and water excretion.
Non-selective beta-adrenergic receptor antagonist; competitively blocks beta1- and beta2-adrenergic receptors, decreasing heart rate, myocardial contractility, and blood pressure.
One capsule orally once daily. Each capsule contains propranolol hydrochloride 160 mg and hydrochlorothiazide 50 mg. Dosage should be individualized; typical maintenance dose is 1 capsule per day.
5 mg orally twice daily, titrated to 10-20 mg twice daily based on response.
None Documented
None Documented
Propranolol: 3-6 hours (parent drug), 8-12 hours (4-hydroxypropranolol active metabolite) with prolonged half-life in hepatic impairment; Hydrochlorothiazide: 6-15 hours, extended in renal impairment (creatinine clearance <30 mL/min).
Terminal elimination half-life: 10-12 hours in healthy adults; prolonged to 20-40 hours in significant renal impairment.
Propranolol: primarily hepatic metabolism to inactive metabolites, <1% excreted unchanged in urine; Hydrochlorothiazide: 50-70% excreted unchanged in urine, remainder as metabolites via renal and biliary routes.
Renal (60-70% unchanged) and fecal (30-40% via biliary excretion as metabolites).
Category C
Category C
Beta Blocker
Beta Blocker